Research programme: immunology therapeutics - BioMed X/Boehringer Ingelheim

Drug Profile

Research programme: immunology therapeutics - BioMed X/Boehringer Ingelheim

Latest Information Update: 22 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioMed X
  • Developer BioMed X; Boehringer Ingelheim
  • Class Immunotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Immunological disorders

Most Recent Events

  • 22 Feb 2017 BioMed X and Boehringer Ingelheim enter into collaboration for immunology therapeutics
  • 06 Feb 2017 Early research in Immunological disorders in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top